9618 Federal Register / Vol. 74, No. 42 / Thursday, March 5, 2009 / Notices 

Reviews was established to aid the 

Advisory Board in carrying out its duty 

to advise the Secretary, HHS, on dose 

reconstruction. 

Matters To Be Discussed: The agenda 

for the Subcommittee meeting includes: 

the selection of an 11th set of dose 

reconstructions for review; discussion of 

cases under review from the 6th, 7th, 

and 8th sets of individual dose 

reconstructions; preparation of a letter 

report on the first 100 dose 

reconstruction cases reviewed; and, 

discussion of selection criteria and 

review rate for 2009. 

The agenda is subject to change as 

priorities dictate. Written comments 

may be submitted from the public. Any 

written comments received will be 

provided at the meeting and should be 

submitted to the contact person below 

well in advance of the meeting. 

This meeting was previously 

scheduled to convene on January 29, 

2009, but was cancelled due to 

inclement weather and airport facility 

inaccessibility. The meeting was 

scheduled to reconvene as soon as 

possible; therefore, this Federal Register 

notice is being published less than 

fifteen days prior to the meeting date. 

Contact Person for More Information: 

Theodore Katz, Designated Federal 

Officer, CDC, NIOSH, 1600 Clifton 

Road, Mailstop E–20, Atlanta, GA 

30333, Telephone (513) 533–6800, Toll 

Free 1 (800) CDC–INFO, E-mail 

ocas@cdc.gov. 

The Director, Management Analysis 

and Services Office, has been delegated 

the authority to sign Federal Register 

notices pertaining to announcements of 

meetings and other committee 

management activities, for both CDC 

and the Agency for Toxic Substances 

and Disease Registry. 

Dated: February 26, 2009. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. E9–4643 Filed 3–4–09; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2008–N–0553] 

Agency Information Collection 

Activities; Submission for Office of 

Management and Budget Review; 

Comment Request; Survey To Evaluate 

the Effectiveness of Mississippi Delta 

Fish Advisories 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing 

that a proposed collection of 

information has been submitted to the 

Office of Management and Budget 

(OMB) for review and clearance under 

the Paperwork Reduction Act of 1995. 

DATES: Fax written comments on the 

collection of information by April 6, 

2009. 

ADDRESSES: To ensure that comments on 

the information collection are received, 

OMB recommends that written 

comments be faxed to the Office of 

Information and Regulatory Affairs, 

OMB, Attn: FDA Desk Officer, FAX: 

202–395–6974, or e-mailed to 

oira_submission@omb.eop.gov. All 

comments should be identified with the 

OMB control number 0910–NEW and 

title ‘‘Survey to Evaluate the 

Effectiveness of Mississippi Delta Fish 

Advisories.’’ Also include the FDA 

docket number found in brackets in the 

heading of this document. 

FOR FURTHER INFORMATION CONTACT: 

Jonna Capezzuto, Office of Information 

Management (HFA–710), Food and Drug 

Administration, 5600 Fishers Lane, 

Rockville, MD 20857, 301–796–3794. 

SUPPLEMENTARY INFORMATION: In 

compliance with 44 U.S.C. 3507, FDA 

has submitted the following proposed 

collection of information to OMB for 

review and clearance. 

Survey to Evaluate the Effectiveness of 

Mississippi Delta Fish Advisories— 

(OMB Control Number 0910–NEW) 

The proposed survey will gather 

information about fishing and fish 

consumption habits in the Mississippi 

Delta region, as well as the respondents’ 

awareness and understanding of the 

Regional Delta Advisory (RDA) issued 

by the Mississippi Department of 

Environmental Quality. Under section 

903(b)(2) of the Federal Food, Drug, and 

Cosmetic Act (21 U.S.C. 393(b)(2)), FDA 

is authorized to conduct research 

relating to foods and to conduct 

educational and public information 

programs relating to the safety of the 

nation’s food supply. In June 2005, the 

Environmental Protection Agency’s 

(EPA’s) Office of Water and FDA’s 

Center for Food Safety and Applied 

Nutrition finalized a Memorandum of 

Understanding (MOU) to enhance 

collaboration between FDA and EPA 

regarding environmental contaminants 

in fish and shellfish and the safety of 

fish and shellfish for U.S. consumers. 

The MOU is available at http:// 

www.epa.gov/waterscience/fish/files/ 

moufdaepa.pdf. 

The proposed study is phase two of a 

two phase study designed to determine 

whether existing fish consumption 

recommendations issued by the State of 

Mississippi are adequately protecting 

sport and subsistence consumers of fish 

harvested from Delta waters. The final 

report of phase one, entitled 

‘‘Recommended Study Design for a 

Survey to Evaluate the Effectiveness of 

Mississippi Delta Fish Advisories,’’ is 

available at http://www.epa.gov/ 

waterscience/fish/technical/msdelta.html. Based on the report cited in 

this paragraph, FDA is conducting the 

proposed survey on behalf of EPA to 

evaluate the effectiveness of the 

Mississippi Delta Fish Advisories. The 

proposed survey will collect 

information on the extent to which 

Delta sport and subsistence fishermen 

and their families are aware of the RDA 

and its recommendations and the extent 

to which the respondents have changed 

their fish consumption behaviors as a 

result of the advisory. The survey will 

also document specific behavior 

changes resulting from the RDA, such as 

increases or decreases in the amount of 

locally harvested fish consumed, 

changes in methods of fish preparation, 

and consumption or avoidance of 

specific species of fish. 

Results of the survey will provide 

EPA information about fishing and fish 

consumption habits in the Mississippi 

Delta region, as well as the respondents’ 

awareness and understanding of the 

RDA. 

The respondents will be selected from 

four counties in the Mississippi Delta 

region. Counties were selected to 

include a mix of rural and non-rural 

areas and areas with major water 

resources affected by the advisory. The 

selected counties are Coahoma, Holmes, 

Leflore, and Washington. Only the part 

of Holmes County that is within the 

advisory area will be included in the 

survey. 

The total sample will include 400 onthe-banks interviews and 600 household 

interviews of sport and subsistence 

fishers who harvest noncommercial fish 


jlentini on PROD1PC65 with NOTICES
Federal Register / Vol. 74, No. 42 / Thursday, March 5, 2009 / Notices 9619 

from the Mississippi Delta advisory 

area, and individuals in the Mississippi 

Delta area who consume wild-caught 

fish from the advisory area. FDA 

estimates that the survey will take 

approximately 18 minutes to complete, 

for a total burden of 300 hours (1,000 x 

0.3 = 300). 

FDA will conduct 6 cognitive 

interviews and 20 pretests prior to 

fielding the survey, for a total additional 

burden of 16 hours. 

In the Federal Register of October 24, 

2008 (73 FR 63487), FDA published a 

60-day notice requesting public 

comment on the information collection 

provisions. No comments were received. 

FDA estimates the burden of this 

collection of information as follows: 

TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN 1

Activity No. of 

respondents 

Annual frequency 

per response 

Total annual 

responses 

Hours per 

response Total hours 

Cognitive Interviews 6 1 6 1 6 

Pretest 20 1 20 .5 10 

Survey 1,000 1 1,000 .30 300 

Total 316 

1There are no capital costs or operating and maintenance costs associated with this collection of information. 

FDA’s burden estimate is based on the 

agency’s prior experience with surveys 

similar to the proposed survey. 

Dated: February 24, 2009. 

Jeffrey Shuren, 

Associate Commissioner for Policy and 

Planning. 

[FR Doc. E9–4644 Filed 3–4–09; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2009–N–0664] 

Risk Communication Advisory 

Committee; Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Risk 

Communication Advisory Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on April 30, 2009, from 8 a.m. to 

5 p.m. and May 1, 2009, from 8 a.m. to 

2 p.m. 

Location: Food and Drug 

Administration, Center for Drug 

Evaluation and Research Advisory 

Committee Conference Room, rm. 1066, 

5630 Fishers Lane, Rockville, MD. 

Contact Person: Lee L. Zwanziger, 

Office of the Commissioner, Office of 

Policy, Planning and Preparedness, 

Office of Planning, Food and Drug 

Administration, 5600 Fishers Lane, rm 

14–90, Rockville, MD 20857, telephone: 

301–827–2895, FAX: 301–827–4050, email: RCAC@fda.hhs.gov, or FDA 

Advisory Committee Information Line, 

1–800–741–8138 (301–443–0572 in the 

Washington, DC area), code 

8732112560. Please call the Information 

Line for up-to-date information on this 

meeting. A notice in the Federal 

Register about last minute modifications 

that impact a previously announced 

advisory committee meeting cannot 

always be published quickly enough to 

provide timely notice. Therefore, you 

should always check the agency’s Web 

site and call the appropriate advisory 

committee hot line/phone line to learn 

about possible modifications before 

coming to the meeting. 

Agenda: On both days the Committee 

will discuss the Agency’s draft risk 

communication strategic plan and will 

be asked for comment and further 

advice, for example, on strategic 

priorities for research on effective risk 

communication. 

FDA intends to make background 

material available to the public no later 

than 2 business days before the meeting. 

If FDA is unable to post the background 

material on its Web site prior to the 

meeting, the background material will 

be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on FDA’s Web site after 

the meeting. Background material is 

available at http://www.fda.gov/ohrms/ 

dockets/ac/acmenu.htm, click on the 

year 2009 and scroll down to the 

appropriate advisory committee link. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before April 23, 2009. Oral 

presentations from the public will be 

scheduled between approximately 1 

p.m. and 2 p.m. on April 30th and 10:30 

to 11:30 a.m. on May 1st. Those desiring 

to make formal oral presentations 

should notify the contact person on or 

before April 23, 2009, and should 

submit a brief statement of the general 

nature of the evidence or arguments 

they wish to present, the names and 

addresses of proposed participants, and 

an indication of the approximate time 

requested to make their presentation. 

Time allotted for each presentation may 

be limited. If the number of registrants 

requesting to speak is greater than can 

be reasonably accommodated during the 

scheduled open public hearing session, 

FDA may conduct a lottery to determine 

the speakers for the scheduled open 

public hearing session. The contact 

person will notify interested persons 

regarding their request to speak by April 

24, 2009. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact Lee L. 

Zwanziger at least 7 days in advance of 

the meeting. 

FDA is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our Web site at 

http://www.fda.gov/oc/advisory/ 

default.htm for procedures on public 

conduct during advisory committee 

meetings. 


jlentini on PROD1PC65 with NOTICES